Status:
RECRUITING
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
Lead Sponsor:
Stanford University
Conditions:
Craniofacial Pain
Migraine
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose administration at surgical sites. The study aims to evaluate the effectiveness of endoscopically-guided inj...
Eligibility Criteria
Inclusion Criteria:
- Patients with a chief complaint of craniofacial pain (migraine, cluster headache, trigeminal autonomic cephalgia, sphenopalatine ganglioneuraligia, paroxysmal hemicrania) who has Stanford Pain & ENT clinic visit
Exclusion Criteria:
- age <18 or >80
- pregnant women
- economically disadvantaged (not able to afford clinic visits/treatments)
- decisionally impaired (unable to obtain informed consent)
- has allergy to bupivacaine
- unable or unwilling to participate plans to participate in another clinical study at any time during this study
Key Trial Info
Start Date :
February 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2030
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04930887
Start Date
February 1 2023
End Date
June 1 2030
Last Update
April 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peter H Hwang
Stanford, California, United States, 94304